By Fineline Cube Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining (dirozalkib), a next-generation oral ALK inhibitor, as first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate unprecedented efficacy with a 31.3-month median progression-free survival (mPFS), more than doubling the 12.9 months achieved with crizotinib, the current standard of care.
Regulatory & Development Timeline
| Milestone | Detail |
|---|---|
| Drug Name | Xuanfeining (dirozalkib) |
| Approval Status | Approved in China (August 2025) for ALK-positive locally advanced or metastatic NSCLC |
| Indication | First-line treatment for ALK-positive advanced NSCLC |
| Clinical Presentation | AACR Annual Meeting 2026 (oral presentation) |
| Trial Designation | DIAMOND-2 Phase III study |
| Company | Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) |
Trial Design & Methodology
- Study Type: Multicenter, randomized, open-label Phase III clinical trial
- Geographic Scope: Conducted exclusively in China
- Comparator: Head-to-head versus crizotinib (current first-line standard)
- Patient Population: ALK-positive advanced NSCLC patients, treatment-naïve to ALK inhibitors
- Primary Endpoint: Investigator-assessed median progression-free survival (mPFS)
- Analysis Population: Modified intention-to-treat (mITT) population
Efficacy Results – Unprecedented PFS Benefit
| Efficacy Parameter | Dirozalkib Group | Crizotinib Group | Hazard Ratio/Improvement |
|---|---|---|---|
| Median PFS | 31.3 months | 12.9 months | HR 0.47 (53% risk reduction) |
| Objective Response Rate (ORR) | 88.5% | Not specified | Significantly superior |
| Median Duration of Response (mDoR) | 32.10 months | Not specified | Significantly superior |
| Disease Control Rate (DCR) | 95.4% | Not specified | Significantly superior |
The 53% reduction in disease progression risk represents one of the most substantial improvements ever demonstrated in ALK-positive NSCLC first-line therapy.
Intracranial Activity – Addressing Critical Unmet Need
| Intracranial Endpoint | Dirozalkib Group | Crizotinib Group |
|---|---|---|
| Intracranial ORR (IC-ORR) | 91.7% | 11.1% |
| Patient Population | Measurable baseline intracranial lesions | Measurable baseline intracranial lesions |
Dirozalkib’s 91.7% intracranial response rate dramatically outperforms crizotinib’s 11.1%, addressing a critical limitation of current ALK inhibitors in managing brain metastases, which occur in up to 60% of ALK-positive NSCLC patients.
Safety Profile – Favorable Tolerability
- Overall Safety: Demonstrated favorable safety and tolerability profile
- Comparison Context: Next-generation ALK inhibitors typically show improved CNS penetration with manageable toxicity compared to first-generation agents like crizotinib
- Clinical Implication: Enhanced safety profile supports long-term treatment adherence and quality of life
Market Impact & Commercial Outlook
- ALK-Positive NSCLC Market: Represents approximately 3-7% of all NSCLC cases globally, with an estimated 40,000 new ALK-positive cases annually in major markets
- Competitive Landscape: Dirozalkib competes with other next-generation ALK inhibitors including alectinib (Alecensa), brigatinib (Alunbrig), and lorlatinib (Lorbrena)
- Market Differentiation: The 31.3-month PFS significantly exceeds historical benchmarks from other next-generation ALK inhibitors (typically 25-34 months), potentially establishing dirozalkib as the new first-line standard
- Global Expansion Potential: Strong Phase III data positions Xuanzhu for international regulatory filings and potential partnership opportunities with global pharmaceutical companies
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for Xuanfeining (dirozalkib). Actual results may differ due to risks including regulatory decisions, competitive dynamics, market adoption rates, and potential confirmatory trial requirements.-Fineline Info & Tech